LCKLSL |
| Catalog No.GC39803 |
Le LCKLSL est un hexapeptide N-terminal et un inhibiteur compétitif de l'annexine A2 (AnxA2).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 533902-29-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles[1].
[1]. Mallika Valapala, et al. A Competitive Hexapeptide Inhibitor of Annexin A2 Prevents Hypoxia-Induced Angiogenic Events. J Cell Sci. 2011 May 1;124(Pt 9):1453-64.
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *